Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Robert Quan Le, MD, PhD, Natasha A Jain, MD, Xin Tian, PhD, Sawa Ito, Kit Lu, MD, Janice Haggerty, RN, Debbie A Draper, RN, Kamna Chawla, MD, MS, A. John Barrett, MD, FRCP, Minoo Battiwalla, MD, MS

Blood (2013) 122 (21): 2124.

https://doi.org/10.1182/blood.V122.21.2124.2124

Published: 2013

Journal Articles

Favorable Outcome and Quality of Life in Patients Surviving 5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.

Robert Quan Le, MD, PhD, Margaret Bevans, RN, PhD, Bipin N. Savani, MD, Sandra Mitchell, CRNP, PhD, Kate Stringaris, MD, Eleftheria K. Koklanaris, RN, BSN, A. John Barrett, MD

Blood (2009) 114 (22): 3312.

https://doi.org/10.1182/blood.V114.22.3312.3312

Published: 2009

Journal Articles

Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Quan Le, MD, PhD, J. Joseph Melenhorst, Ph.D., Bipin N. Savani, MD, Brenna Hill, MPHIL, Sarfraz Memon, MD, Aarthi Shenoy, MD, Nancy F. Hensel, Elefteria K Koklanaris, RN, BSN, Keyvan Keyvanfar, BS, Fran Hakim, Ph.D., Daniel Douek, MD, PhD, A. John Barrett, MD

Blood (2008) 112 (11): 1173.

https://doi.org/10.1182/blood.V112.11.1173.1173

Published: 2008

Journal Articles

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Agnes S. M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Katayoun Rezvani, MD, PhD, Aarthi Shenoy, MD, Eleftheria K. Koklanaris, BSN, Laura Musse, MSN, Theresa Donohue, MS, Quan Le, MD, PhD, John M. Goldman, MD, A. John Barrett, MD

Blood (2008) 112 (11): 1107.

https://doi.org/10.1182/blood.V112.11.1107.1107

Published: 2008

Journal Articles

Identification of a Shared CD4+ and CD8+ T Cell Epitope within Human Neutrophil Elastase for Peptide Vaccination in HLA-A02 Negative Leukemia Patients.

Quan Le, MD, PhD, J. Joseph Melenhorst, PhD, Rachel E. Hewitt, Nancy Hensel, A. John Barrett, MD

Blood (2007) 110 (11): 1803.

https://doi.org/10.1182/blood.V110.11.1803.1803

Published: 2007

Journal Articles

Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.

Quan Le, MD, PhD, J. Joseph Melenhorst, PhD, Nancy Hensel, Rhoda Eniafe, A. John Barrett, MD

Blood (2007) 110 (11): 1807.

https://doi.org/10.1182/blood.V110.11.1807.1807

Published: 2007

Journal Articles

Hepatitis B Reverse Seroconversion in Long Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation.

Quan Le, MD, PhD, Bipin N. Savani, MD, Aarthi Shenoy, MD, Eleftheria Kozanas, RN, BSN, A. John Barrett, MD

Blood (2007) 110 (11): 1978.

https://doi.org/10.1182/blood.V110.11.1978.1978

Published: 2007

NARROW

Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Favorable Outcome and Quality of Life in Patients Surviving 5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.

Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Identification of a Shared CD4+ and CD8+ T Cell Epitope within Human Neutrophil Elastase for Peptide Vaccination in HLA-A02 Negative Leukemia Patients.

Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.

Hepatitis B Reverse Seroconversion in Long Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Favorable Outcome and Quality of Life in Patients Surviving 5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.

Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Identification of a Shared CD4+ and CD8+ T Cell Epitope within Human Neutrophil Elastase for Peptide Vaccination in HLA-A02 Negative Leukemia Patients.

Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.

Hepatitis B Reverse Seroconversion in Long Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only